Azaserine
(Synonyms: 偶氮丝胺酸; CI-337; O-Diazoacetyl-L-serine; P-165) 目录号 : GC14874
Azaserine是一种谷氨酰胺拮抗剂。
Cas No.:115-02-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Azaserine is a glutamine antagonist [1]. Azaserine inhibits glutamine amidotransferase, interfering with the production of purine nucleotides and thereby inhibiting DNA and RNA synthesis [2]. Azaserine inhibits the hexamine biosynthesis pathway, reducing the production of UDP-N-acetylglucosamine and protein O-glycosylation, thereby affecting cellular glucose metabolism and protein post-translational modification [3]. Azaserine is primarily used to treat pancreatic tumors [4].
In R28 cells, Azaserine (0.1μM; 24h) blocks the entry of glucose into the hexosamine biosynthesis pathway (HBP), thereby reversing the inhibition of high glucose on the anti-apoptotic effect of insulin [5]. In Raji cells, Azaserine (5μM; 24h) inhibits cell growth [6].
References:
[1]. Livingston R B, Venditti J M, Cooney D A, et al. Glutamine antagonists in chemotherapy[J]. Advances in Pharmacology, 1971, 8: 57-120.
[2]. SARTORELLI A C, BOOTH B A. Inhibition of the synthesis of thymine nucleotides by azaserine[J]. Molecular Pharmacology, 1967, 3(1): 71-80.
[3]. Rajapakse A G, Ming X F, Carvas J M, et al. The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects[J]. American Journal of Physiology-Heart and Circulatory Physiology, 2009, 296(3): H815-H822.
[4]. Longnecker D S, Curphey T J. Adenocarcinoma of the pancreas in azaserine-treated rats[J]. Cancer research, 1975, 35(8): 2249-2257.
[5]. Nakamura M, Barber A J, Antonetti D A, et al. Excessive hexosamines block the neuroprotective effect of insulin and induce apoptosis in retinal neurons[J]. Journal of Biological Chemistry, 2001, 276(47): 43748-43755.
[6]. O'Driscoll M, Macpherson P, Xu Y Z, et al. The cytotoxicity of DNA carboxymethylation and methylation by the model carboxymethylating agent azaserine in human cells[J]. Carcinogenesis, 1999, 20(9): 1855-1862.
Azaserine是一种谷氨酰胺拮抗剂 [1]。Azaserine抑制谷氨酰胺酰胺转移酶，干扰嘌呤核苷酸的生成，从而抑制DNA和RNA的合成 [2]。Azaserine抑制六胺生物合成途径，减少UDP-N-乙酰葡萄糖胺的生成和蛋白质O-糖基化，从而影响细胞葡萄糖代谢和蛋白质翻译后修饰 [3]。Azaserine主要用于治疗胰腺肿瘤 [4]。
在R28细胞中，Azaserine （0.1μM；24h）阻断葡萄糖进入六胺生物合成途径（HBP），从而逆转高糖对胰岛素抗凋亡作用的抑制 [5]。在Raji细胞中，Azaserine（5μM；24h）抑制细胞生长 [6]。
| Cell experiment [1]: | |
Cell lines | R28 cells |
Preparation Method | After incubation for 24 hours in 5mM glucose, 20mM glucose, or 5mM glucose plus 1.5mM glucosamine (with or without 10nM insulin or 0.1μM Azaserine), 100mm plates of R28 cells were washed once with ice-cold phosphate buffer and homogenized in 0.5mL of 0.3mM perchloric acid. Cells were pelleted by centrifugation, and the perchloric acid was extracted from the supernatant with two volumes of 1:4 trioctylamine:1,1,2-trichlorofluoroethane. The aqueous phase was stored at −80℃ and analyzed within 5 days. Nucleotide-linked hexoses and hexosamines were separated and determined by anion-exchange high-pressure liquid chromatography. UDP-HexNAc and UDP-hexose were quantified by UV absorption and compared to external standards. |
Reaction Conditions | 0.1μM; 24h |
Applications | Azaserine blocks the entry of glucose into the hexosamine biosynthesis pathway (HBP), thereby reversing the inhibition of high glucose on the anti-apoptotic effect of insulin. |
References: | |
| Cas No. | 115-02-6 | SDF | |
| 别名 | 偶氮丝胺酸; CI-337; O-Diazoacetyl-L-serine; P-165 | ||
| 化学名 | O-(2-diazoacetyl)-L-serine | ||
| Canonical SMILES | O=C(C=[N+]=[N-])OC[C@H](N)C(O)=O | ||
| 分子式 | C5H7N3O4 | 分子量 | 173.1 |
| 溶解度 | ≥ 21.4 mg/mL in Water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.777 mL | 28.885 mL | 57.7701 mL |
| 5 mM | 1.1554 mL | 5.777 mL | 11.554 mL |
| 10 mM | 577.7 μL | 2.8885 mL | 5.777 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet